Tonix Pharmaceuticals Highlights Fibromyalgia Drug Data at Pain Medicine Conference
Event summary
- Tonix Pharmaceuticals will present data on Tonmya™ at the 2026 AAPM PainConnect Annual Meeting in Salt Lake City.
- Poster titled 'Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia' to be presented March 6, 2026.
- Tonmya™ (cyclobenzaprine HCl sublingual tablets) is Tonix's flagship fibromyalgia treatment approved over 15 years after the last new therapy.
- Company also developing CNS and immunology pipeline including TNX-4800 for Lyme disease prophylaxis.
The big picture
Tonix Pharmaceuticals is positioning itself as a key player in the fibromyalgia treatment space with its recently approved Tonmya™. The presentation of positive clinical data at a major pain medicine conference underscores the company's strategic focus on central nervous system therapies. With additional pipeline candidates in development, Tonix aims to address multiple high-unmet medical needs across CNS and immunology indications.
What we're watching
- Pipeline Expansion
- How Tonix will leverage Tonmya's success in fibromyalgia to advance its Phase 2 trials for major depressive disorder and acute stress disorder.
- Market Differentiation
- Whether Tonmya can establish itself as a preferred treatment option in the competitive fibromyalgia market.
- Commercial Execution
- The pace at which Tonix can expand its CNS commercial infrastructure to support multiple product launches.
Related topics